Lutris Pharma is a clinical stage biopharmaceutical company focused on improving anti-cancer therapy effectiveness and quality of life for patients who are being treated with EGFR (Epidermal Growth Factor Receptor) inhibitors or with radiation, where dermal toxicity often leads to a reduction of anti-cancer therapy compliance. The company aims to provide novel topical therapies in order to mitigate these side effects. Lutris Pharma’s lead asset, LUT014, a topical B-Raf Inhibitor, is a proprietary, first-in-class, small molecule currently in a phase 2 clinical trial in metastatic colorectal cancer patients with EGFR inhibitor induced acneiform lesions and a phase 1/2 study for the treatment of radiation-induced dermatitis.
Company Details
- Employees
- 5
- Address
- 27 Habarzel Street, Tel Aviv,israel
- Industry
- Biotechnology
- Website
- https://www.lutris-pharma.com/
- Keywords
- Engineer jobs.
- HQ
- Tel Aviv
Lutris Pharma Questions
Lutris Pharma's website is https://www.lutris-pharma.com/
Lutris Pharma's LinkedIn profile is https://il.linkedin.com/company/lutris-phama
Lutris Pharma has
5 employees.
View email and phone details for 5
employees at Lutris Pharma.
Lutris Pharma's industry is
Biotechnology
Lutris Pharma's top competitors are
Enzymit,
Neurotrigger,
Nrgene Ltd.,
Oncohost,
Cytoreason,
Immpact Bio,
Polypid Ltd.,
Magentiq Eye Ltd.,
Lyell Immunopharma,
Identifai Genetics.
Lutris Pharma's categories are Biotechnology
